Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ACCV
4. LLY
5. FLG
6. META
7. FICO
8. GMAB
9. QQQ
10. TSLA

Go back to Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong

September 1, 2026 7:30 AM EDT

4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen

Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile

New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life

BEDFORD, Mass.andCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) --... More